Tag: Crohn’s disease
CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings
Multi-Omic and dietary analysis of Crohn’s disease identifies pathogenetic factors
Novel classification system for perianal fistulising Crohn’s disease
Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease
Segmental colectomy beneficial over total colectomy in Chrohn’s disease
Stopping infliximab but not antimetabolites leads to more relapses in Crohn’s disease
VEDOKIDS: Vedolizumab seems effective in paediatric IBD
Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease
Subcutaneous infliximab versus subcutaneous vedolizumab in IBD
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Risankizumab more efficacious in colonic than in ileal Crohn’s disease
Filgotinib seems promising for perianal fistulising Crohn’s disease
Risankizumab meets primary endpoints in maintenance study for CD patients
Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD
Serious adverse events put a stop to ASTIClite trial for CD
UEGW 2021 Highlights Podcast
Blood proteins predicting relapse in CD identified
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Extracellular RNA has potential as a non-invasive biomarker in IBD
Ustekinumab safe and effective in elderly CD patients
Early clinical remission and response following risankizumab therapy in CD
Surgical closure plus anti-TNF outperforms anti-TNF alone for perianal fistula
Risk of hospitalisation and surgery linked to IBD biological
Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease
First randomised T2T trial using endoscopy to guide dose escalation
Resolution of mucosal inflammation has dramatic effect
Role of immune cells in intestinal fibrosis
Association between meat consumption and IBD risk
CD exclusion diet corrects dysbiosis
Increased risk of small bowel cancer in IBD
Increased incidence of colorectal cancer and death in CD
Risk of rectal, anal cancer increased in perianal CD
On the cutting edge of pathology and surgery
Impact of strategies on intestinal resection rate
Early ileocaecal resection in CD patients failing conventional treatment
Biologics before surgery in IBD do not elevate infection risk
Top-down infliximab superior to step-up in children with CD
Ustekinumab in CD: a T2T trial
Subcutaneous vedolizumab maintenance therapy in CD
Vedolizumab treatment persistence and safety
Pipeline of IBD drugs
Open-label extension study of risankizumab: final results
Clinical remission after dose escalation of upadacitinib
Multi-omics help describe CD phenotypes
Impact of biologicals on faecal microbiota
Ileal microbiota predict recurrence in CD patients after resection
Decreased microvilli length in CD patients
Plant-based foods and Mediterranean diet associated with healthy gut microbiome
Phase 2 data shows benefit for mirikizumab in CD patients
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
The costs and benefits of biologicals
Ustekinumab as maintenance therapy and with shortened interval
Early remission of Crohn’s disease prevents progression
Microbial composition and psychological wellbeing
Immune cells and microbes: a happy marriage?
Gene expression signature predicts non-response
Proactive adalimumab trough measurements
Switching to biosimilar bDMARDs is safe and efficacious
Vedolizumab induces endoscopic remission and healing in refractory CD
